Evidence map›Paper›PMID 41025426›Full record

ArticleClinical and translational medicine2025

Distinct molecular subtypes of KRAS

Haitang Yang, Anshun Zhu, Yongliang Niu, Wenyan Ma, Ke Xu, Yunxuan Jia, Weijiao Xu, Baicheng Zhao, Enshuo Zhang, Jiaying Jia and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical and translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Distinct molecular subtypes of KRASClinical and translational medicine · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Haitang YangDepartment of Thoracic Surgery, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Anshun ZhuDepartment of Thoracic Surgery, First Affiliated Hospital of Wenzhou Medical University, Wenzhou Medical University, Wenzhou, China.
Yongliang NiuDepartment of Respiratory and Critical Care Medicine, No. 2 People's Hospital of Fuyang City, Fuyang Infectious Disease Clinical College of Anhui Medical University, Fuyang, China.
Wenyan MaClinical Research Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China.
Ke XuDepartment of Thoracic Surgery, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Yunxuan JiaDepartment of Thoracic Surgery, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Weijiao XuDepartment of Thoracic Surgery, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Baicheng ZhaoDepartment of Thoracic Surgery, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Enshuo ZhangDepartment of Thoracic Surgery, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Jiaying JiaDepartment of Thoracic Surgery, First Affiliated Hospital of Wenzhou Medical University, Wenzhou Medical University, Wenzhou, China.
Shunqing LiangDepartment of Medicine, University of Minnesota Twin Cities, Minneapolis, Minnesota, USA.
Patrick DornDepartment of General Thoracic Surgery, Inselspital, Bern University Hospital, Bern, Switzerland.
Gang LiuDepartment of Thoracic Surgery, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Ren-Wang PengDepartment of General Thoracic Surgery, Inselspital, Bern University Hospital, Bern, Switzerland.
Feng YaoDepartment of Thoracic Surgery, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.ORCID 0000-0002-9635-9581

Funding

Basic Foundation Program for Youth of Shanghai Chest Hospital 2021YNJCQ2Clinical Research Special Fund Project of Shanghai Chest Hospital 2024IIT-Q007Fundamental Research Funds for the Central Universities YG2024QNA51Fundamental Research Funds for the Central Universities YG2025ZD14National Natural Science Foundation of China 82202925National Natural Science Foundation of China 8237112887Swiss National Science Foundation 310030-192648Swiss National Science Foundation 320030-231251
6 · The paper itself

Abstract

backgroundKRAS

methodsTranscriptomic analysis of KRAS

resultsWe identified three distinct molecular subtypes (KC1, KC2 and KC3) of KRAS

conclusionsThese findings illuminate the intricate interplay between tumour subtypes, microenvironmental factors and therapeutic responses, offering a robust framework for improved patient stratification and the development of personalised therapeutic strategies KRAS KEY POINTS: Three novel molecular subtypes (KC1, KC2 and KC3) of KRAS

Indexed as

Adenocarcinoma of LungLung NeoplasmsProto-Oncogene Proteins p21(ras)Tumor MicroenvironmentHumansMutationPrognosisKRAS protein, humanProto-Oncogene Proteins p21(ras)KRAS mutationlung adenocarcinomamolecular subtypesprecision oncologytreatment responsetumour immune microenvironment

Identifiers

PMID41025426
PMCPMC12481212

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.